Department of Pharmaceutical Management, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
Department of Public Health, School of Allied Health Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
Diabetes Res Clin Pract. 2020 Sep;167:108349. doi: 10.1016/j.diabres.2020.108349. Epub 2020 Jul 23.
While there are rampant deaths reported worldwide due to novel corona virus (COVID-19) on one side, hypertension, diabetes and renal failure are emerging comorbidities with mortality risk due to respiratory failure on the other side. The link of these morbidities with renin angiotensin system (RAS) and angiotensin converting enzyme-2 (ACE2) as the site of the multiplication of COVID-19 has widely been accepted. The objective of this research report was to delineate the clinical characteristics with COVID-19 infection with RAS and to consider its significance not just for the search of novel antiviral drugs, but for the management and prevention of death of patients with COVID-19.
It was a retrospective case series analysis of demographic and clinical data with associated comorbidities of 206 deaths reported in India up to 10th April 2020. The data were available from the official release from Ministry of Health and Family welfare, Government of India. This was followed by a literature search to correlate the available evidence for their possible relationship with RAS.
The demographic data were consistent with those reported from other countries. The death (53.4%) was more common in patients with age above 60 years and men (69.3%) were more susceptible as compared to women (30.68%).We found that 50.5% of the deceased patients had pre-existing comorbidities. Diabetes and hypertension were the major comorbidities in 27.8% and 22.1% of the deceased cases respectively. Although respiratory and cardiac problems were prevalent at the time of death, the pre-existing pulmonary disease was comparatively less prevalent. Only 13.6% of the deceased were having pre-existing respiratory problems and 6.2% had cardiac ailments. We could correlate the reports that RAS plays a significant role in the prognosis of the disease.
Patients with cardiovascular diseases, diabetes mellitus and hypertension are at greater risk for developing COVID-19 infection. There may be massive derangement of the entire RAS after the attack of COVID-19 and hence, patients with these pre-existing comorbidities and on ACE inhibitors or angiotensin receptor blockers should be monitored carefully considering the role of RAS in the prognosis of COVID-19 infections.
一方面,由于新型冠状病毒(COVID-19)的肆虐,世界各地都有报道死亡病例;另一方面,高血压、糖尿病和肾衰竭等疾病也成为与呼吸衰竭相关的合并症,导致死亡率上升。这些疾病与肾素血管紧张素系统(RAS)和血管紧张素转换酶 2(ACE2)之间的联系已被广泛接受,ACE2 是 COVID-19 病毒繁殖的部位。本研究报告的目的是描述 COVID-19 感染与 RAS 的临床特征,并考虑其不仅对寻找新型抗病毒药物具有重要意义,而且对 COVID-19 患者的管理和预防死亡也具有重要意义。
这是对截至 2020 年 4 月 10 日印度报告的 206 例死亡病例的人口统计学和临床数据的回顾性病例系列分析。数据来自印度卫生部和家庭福利部的官方发布。之后,我们进行了文献检索,以将现有证据与 RAS 进行关联。
人口统计学数据与其他国家报告的数据一致。死亡(53.4%)更常见于 60 岁以上的患者,男性(69.3%)比女性(30.68%)更容易死亡。我们发现,50.5%的死亡患者存在既往合并症。糖尿病和高血压分别是 27.8%和 22.1%死亡病例的主要合并症。尽管在死亡时存在呼吸和心脏问题,但既往肺部疾病的患病率相对较低。只有 13.6%的死亡患者存在既往呼吸系统问题,6.2%的死亡患者存在心脏疾病。我们可以将 RAS 在疾病预后中起重要作用的报道进行关联。
患有心血管疾病、糖尿病和高血压的患者患 COVID-19 感染的风险更高。COVID-19 感染后,整个 RAS 可能会出现严重失调,因此,对于存在这些既往合并症且正在服用 ACE 抑制剂或血管紧张素受体阻滞剂的患者,应考虑 RAS 在 COVID-19 感染预后中的作用,进行仔细监测。